CVS Health Updates 2025 Guidance; Issues 2026 Outlook

CVS Health raised its 2025 outlook, increasing adjusted EPS to $6.60–$6.70 (from $6.55–$6.65), adjusted operating income to $14.22–$14.39 billion (from $14.14–$14.31 billion) and bumping total revenue guidance to at least $400.0 billion (from $397.3 billion), while narrowing the expected GAAP loss per share to $0.32–$0.22. The company also provided 2026 targets—revenues of at least $400.0 billion, adjusted operating income of $15.07–$15.41 billion, GAAP EPS $5.94–$6.14 and adjusted EPS $7.00–$7.20—and reiterated a mid‑teens adjusted EPS CAGR through 2028. CVS said it will launch a new technology products and services offering focused on engagement-as-a-service, and its shares were up about 3% premarket to $79.00.

Analysis

CVS Health raised its 2025 outlook, increasing adjusted EPS to $6.60–$6.70 from $6.55–$6.65, lifting adjusted operating income to $14.22–$14.39 billion from $14.14–$14.31 billion, and boosting total revenue guidance to at least $400.0 billion from $397.3 billion. Management narrowed the expected GAAP loss per share to $0.32–$0.22 from $0.34–$0.24, and the stock traded up roughly 3% premarket to $79.00.

The company initiated 2026 guidance with revenue of at least $400.0 billion, adjusted operating income of $15.07–$15.41 billion, GAAP EPS of $5.94–$6.14 and adjusted EPS of $7.00–$7.20, and reiterated a mid‑teens adjusted EPS CAGR through 2028. The swing from a 2025 GAAP loss to a positive 2026 GAAP EPS range implies significant timing or one‑off items in 2025 and management confidence in returning to positive GAAP earnings next year. CVS also announced a technology products and services launch focused on Engagement as a Service, signaling strategic diversification beyond traditional pharmacy and health services.

Raised near‑term guidance and multi‑year targets suggest operational momentum and potential margin expansion, but the gap between GAAP and adjusted metrics and execution of the new tech offering are key risks. Investors should monitor quarterly confirmation of the raised adjusted operating income and revenue lines and watch for concrete early results from the Engagement‑as‑a‑Service initiative as primary catalysts or warning signs.

Key Decisions for Investors

• Consider a tactical accumulation or modest overweight given the raised 2025/2026 guidance and positive premarket reaction, but size positions conservatively due to 2025 GAAP volatility
• Monitor upcoming quarterly results for confirmation of the higher adjusted operating income, revenue and adjusted EPS guidance and be prepared to trim on misses
• Model valuations using the 2026 GAAP EPS range and management’s mid‑teens adjusted EPS CAGR as base cases but stress‑test scenarios that assume slower execution or delayed monetization
• Track early adoption and monetization metrics for the Engagement‑as‑a‑Service offering as a potential upside catalyst and consider adding exposure on clear signs of margin contribution